StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX - Free Report) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock.
Other equities analysts have also issued research reports about the company. Benchmark reissued a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reissued a "buy" rating and set a $5.00 price target on shares of VolitionRx in a research report on Wednesday, March 12th.
Get Our Latest Report on VolitionRx
VolitionRx Stock Up 1.0 %
Shares of NYSE:VNRX traded up $0.01 during trading on Thursday, hitting $0.55. The stock had a trading volume of 289,541 shares, compared to its average volume of 178,720. The company has a market capitalization of $50.97 million, a PE ratio of -1.53 and a beta of 1.09. The firm's fifty day moving average is $0.60 and its 200 day moving average is $0.64. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.02.
Institutional Investors Weigh In On VolitionRx
Hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC bought a new position in shares of VolitionRx during the fourth quarter valued at $29,000. Millennium Management LLC purchased a new stake in VolitionRx during the 4th quarter valued at about $36,000. Northern Trust Corp increased its stake in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. Geode Capital Management LLC raised its holdings in VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock worth $439,000 after buying an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. lifted its stake in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. 8.09% of the stock is owned by institutional investors.
About VolitionRx
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Further Reading
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
